Search Articles — Sudonull

https://sudonull.com/moderna-s-personalized-mrna-vaccine-against-pancreatic-cancer-78-effect

Moderna released a personalized mRNA vaccine against pancreatic cancer: remission in 78% of patients over 18 months. FDA accelerated approval. Analysis of efficacy and risks.

https://sudonull.com/cambridge-ai-based-vaccine-first-phase-of-trials

Cambridge scientists and DIOSynVax have created a coronavirus vaccine using AI. First phase results: safe and tolerable. Learn about the breakthrough in vaccinology.

https://sudonull.com/gofintech-and-quregenai-quantum-drug-discovery-in-hong-kong

GoFintech Quantum Innovation and QureGenAI Biotech signed a memorandum to establish a quantum computing center in Hong Kong. Learn how the deal is transforming the pharmaceutical and AI market.

https://sudonull.com/crispr-pencil-gene-therapy-n-1-saved-an-infant

Doctors edited a newborn's liver by assembling therapy for a unique mutation. Learn how CRISPR-pencil is changing regulation and the future of medicine.

https://sudonull.com/daraxonacib-for-pancreatic-cancer-risks-and-survival

The drug daraxonacib doubled survival in pancreatic cancer but does not cure. Learn about mechanisms, side effects, and real limits of the breakthrough. Read the analysis.

https://ymaho.com/m-a-in-pharmaceuticals-deal-boom-due-to-ai-drug-development

Big Pharma spends billions on buying AI startups to shorten the R&D cycle. Learn how AI is changing the M&A market. Detailed analysis.

https://ymaho.com/marne-cel-fda-approval-gene-therapy-for-lad-i

FDA approved Marne-Cel for children with severe LAD-I: 100% survival in trials. Learn how Rocket Pharmaceuticals turned rejections into a breakthrough.

https://ymaho.com/big-pharma-mergers-84-billion-in-deals-in-a-quarter

The $300 Billion Patent Cliff Drove Big Pharma to Spend $84 Billion on Biotech Deals in Q1. Find Out Which Companies Are Buying and Why.

https://ymaho.com/vepdegestrant-the-first-breast-cancer-protein-degrader

FDA approved vepdegestrant — the first PROTAC degrader for breast cancer with ESR1 mutation. Learn how it destroys resistance and what will change in therapy. Details here.

https://ymaho.com/langlara-fda-approved-chinese-insulin-biosimilar

FDA approved interchangeable biosimilar insulin glargine Langlara from Chinese Sunshine Lake. Learn how this will change the US market and prices for patients. Detailed analysis inside.

https://ymaho.com/fda-approved-langlara-as-an-interchangeable-biosimilar-of-insulin-glargine

FDA granted Langlara interchangeable biosimilar status to Lantus. Learn how this will change the US insulin market and expand patient access to therapy.

https://ymaho.com/sarna-vaccine-for-cats-ema-decision-as-a-breakthrough-for-medicine

EMA has approved the first RNA vaccine for animals. We analyze why this decision opens a new wave in human medicine and changes the market. Get insights.

https://ymaho.com/biosimilar-without-phase-3-fda-and-ema-rewrite-the-rules

FDA and EMA approved skipping Phase 3 for Herceptin biosimilar AP063. Learn how this decision will change the biosimilar market and accelerate access to cancer therapy.

https://ymaho.com/fda-will-approve-subcutaneous-lecanemab-in-august-2026

Analysis of the FDA decision postponement for Leqembi IQLIK to August 24: why this is a signal for approval, not a delay. Benefits for Alzheimer's patients and market forecast. Read key takeaways.

https://ymaho.com/fda-may-approve-ophthalmic-bevacizumab-lytenava

Analysis of the regulatory paradox: why the FDA rejected it three times, while Europe approved it. Learn how the Lytenava decision will change the $16 billion AMD market.